JP2018193382A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018193382A5 JP2018193382A5 JP2018135444A JP2018135444A JP2018193382A5 JP 2018193382 A5 JP2018193382 A5 JP 2018193382A5 JP 2018135444 A JP2018135444 A JP 2018135444A JP 2018135444 A JP2018135444 A JP 2018135444A JP 2018193382 A5 JP2018193382 A5 JP 2018193382A5
- Authority
- JP
- Japan
- Prior art keywords
- degrees
- peaks
- xrpd
- solid form
- xrpd pattern
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 126
- 239000007787 solid Substances 0.000 claims description 86
- 150000001875 compounds Chemical class 0.000 claims description 47
- 239000013078 crystal Substances 0.000 claims description 26
- 150000003840 hydrochlorides Chemical class 0.000 claims description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000012453 solvate Substances 0.000 claims description 10
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 6
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 claims description 3
- 125000005490 tosylate group Chemical class 0.000 claims description 3
- 230000004580 weight loss Effects 0.000 claims 12
- 208000027866 inflammatory disease Diseases 0.000 claims 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 6
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 4
- 238000010438 heat treatment Methods 0.000 claims 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 2
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940125782 compound 2 Drugs 0.000 claims 2
- FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical class OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 claims 2
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 201000004997 drug-induced lupus erythematosus Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 description 17
- 150000008064 anhydrides Chemical class 0.000 description 3
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 2
- 0 O=*(c1c(C2)c(OCc3ccc(CN4CCOCC4)cc3)ccc1)N2[C@@](CCC(N1)=O)C1=O Chemical compound O=*(c1c(C2)c(OCc3ccc(CN4CCOCC4)cc3)ccc1)N2[C@@](CCC(N1)=O)C1=O 0.000 description 2
- VOEDQAONRWQWFZ-NRFANRHFSA-N O=C(C1=C(C2)C(OCc3ccc(CN4CCOCC4)cc3)=CCC1)N2[C@@H](CCC(N1)=O)C1=O Chemical compound O=C(C1=C(C2)C(OCc3ccc(CN4CCOCC4)cc3)=CCC1)N2[C@@H](CCC(N1)=O)C1=O VOEDQAONRWQWFZ-NRFANRHFSA-N 0.000 description 2
- IXZOHGPZAQLIBH-UHFFFAOYSA-N O=C(c1c(C2)c(OCc3ccc(CN4CCOCC4)cc3)ccc1)N2C(CCC(N1)=O)C1=O Chemical compound O=C(c1c(C2)c(OCc3ccc(CN4CCOCC4)cc3)ccc1)N2C(CCC(N1)=O)C1=O IXZOHGPZAQLIBH-UHFFFAOYSA-N 0.000 description 2
- IXZOHGPZAQLIBH-NRFANRHFSA-N O=C(c1c(C2)c(OCc3ccc(CN4CCOCC4)cc3)ccc1)N2[C@@H](CCC(N1)=O)C1=O Chemical compound O=C(c1c(C2)c(OCc3ccc(CN4CCOCC4)cc3)ccc1)N2[C@@H](CCC(N1)=O)C1=O IXZOHGPZAQLIBH-NRFANRHFSA-N 0.000 description 2
- KDODKCNOLNSRCI-DEOSSOPVSA-N CC(C1=C(CN[C@@H](CCC(N2)=O)C2=O)C(OCc2ccc(CN3CCOCC3)cc2)=CCC#C1)=O Chemical compound CC(C1=C(CN[C@@H](CCC(N2)=O)C2=O)C(OCc2ccc(CN3CCOCC3)cc2)=CCC#C1)=O KDODKCNOLNSRCI-DEOSSOPVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- OZHXLPTYODOEFI-UHFFFAOYSA-N O=C(C(C=CC1)=C(C2)C1OCc1ccc(CN3CCOCC3)cc1)N2C(CCC(N1)=O)C1=O Chemical compound O=C(C(C=CC1)=C(C2)C1OCc1ccc(CN3CCOCC3)cc1)N2C(CCC(N1)=O)C1=O OZHXLPTYODOEFI-UHFFFAOYSA-N 0.000 description 1
- VEJUANQWUJGECH-YFPLAWBCSA-N O=C(CC[C@@H]1N(C2)C3OC3c3c2c(OCc2ccc(CN4CCOCC4)cc2)ccc3)NC1=O Chemical compound O=C(CC[C@@H]1N(C2)C3OC3c3c2c(OCc2ccc(CN4CCOCC4)cc2)ccc3)NC1=O VEJUANQWUJGECH-YFPLAWBCSA-N 0.000 description 1
- FSAIPDALTWLINA-UHFFFAOYSA-N O=C(c1c(C2)c(OCC3=CCC(CN4CCOCC4)C=C3)ccc1)N2C(CCC(N1)=O)C1=O Chemical compound O=C(c1c(C2)c(OCC3=CCC(CN4CCOCC4)C=C3)ccc1)N2C(CCC(N1)=O)C1=O FSAIPDALTWLINA-UHFFFAOYSA-N 0.000 description 1
- RVCQPJFZKRZBQK-QFIPXVFZSA-N O=C(c1c(C2)c(OCCc3ccc(CN4CCOCC4)cc3)ccc1)N2[C@@H](CCC(N1)=O)C1=O Chemical compound O=C(c1c(C2)c(OCCc3ccc(CN4CCOCC4)cc3)ccc1)N2[C@@H](CCC(N1)=O)C1=O RVCQPJFZKRZBQK-QFIPXVFZSA-N 0.000 description 1
- URNOWHKBGQPDIJ-XEGCMXMBSA-N OC([C@H](CC1)N(Cc2c3cccc2OCc2ccc(CN4CCOCC4)cc2)C3=O)NC1=O Chemical compound OC([C@H](CC1)N(Cc2c3cccc2OCc2ccc(CN4CCOCC4)cc2)C3=O)NC1=O URNOWHKBGQPDIJ-XEGCMXMBSA-N 0.000 description 1
- XMDMKYZTWXTUTD-UHFFFAOYSA-N OC(c1c(C2)c(OCc3ccc(CN4CCOCC4)cc3)ccc1)N2C(CCC(N1)=O)C1=O Chemical compound OC(c1c(C2)c(OCc3ccc(CN4CCOCC4)cc3)ccc1)N2C(CCC(N1)=O)C1=O XMDMKYZTWXTUTD-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261681484P | 2012-08-09 | 2012-08-09 | |
| US61/681,484 | 2012-08-09 | ||
| JP2015526692A JP6419072B2 (ja) | 2012-08-09 | 2013-08-08 | （ｓ）−３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンの塩及び固体形態、並びにそれらを含有する組成物及び使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526692A Division JP6419072B2 (ja) | 2012-08-09 | 2013-08-08 | （ｓ）−３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンの塩及び固体形態、並びにそれらを含有する組成物及び使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020081266A Division JP7174735B2 (ja) | 2012-08-09 | 2020-05-01 | （ｓ）－３－（４－（（４－（モルホリノメチル）ベンジル）オキシ）－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオンの塩及び固体形態、並びにそれらを含有する組成物及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018193382A JP2018193382A (ja) | 2018-12-06 |
| JP2018193382A5 true JP2018193382A5 (cg-RX-API-DMAC7.html) | 2019-01-31 |
| JP6954869B2 JP6954869B2 (ja) | 2021-10-27 |
Family
ID=49054882
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526692A Active JP6419072B2 (ja) | 2012-08-09 | 2013-08-08 | （ｓ）−３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンの塩及び固体形態、並びにそれらを含有する組成物及び使用方法 |
| JP2018135444A Active JP6954869B2 (ja) | 2012-08-09 | 2018-07-19 | （ｓ）−３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンの塩及び固体形態、並びにそれらを含有する組成物及び使用方法 |
| JP2020081266A Active JP7174735B2 (ja) | 2012-08-09 | 2020-05-01 | （ｓ）－３－（４－（（４－（モルホリノメチル）ベンジル）オキシ）－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオンの塩及び固体形態、並びにそれらを含有する組成物及び使用方法 |
| JP2022127689A Active JP7431900B2 (ja) | 2012-08-09 | 2022-08-10 | （ｓ）－３－（４－（（４－（モルホリノメチル）ベンジル）オキシ）－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオンの塩及び固体形態、並びにそれらを含有する組成物及び使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526692A Active JP6419072B2 (ja) | 2012-08-09 | 2013-08-08 | （ｓ）−３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンの塩及び固体形態、並びにそれらを含有する組成物及び使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020081266A Active JP7174735B2 (ja) | 2012-08-09 | 2020-05-01 | （ｓ）－３－（４－（（４－（モルホリノメチル）ベンジル）オキシ）－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオンの塩及び固体形態、並びにそれらを含有する組成物及び使用方法 |
| JP2022127689A Active JP7431900B2 (ja) | 2012-08-09 | 2022-08-10 | （ｓ）－３－（４－（（４－（モルホリノメチル）ベンジル）オキシ）－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオンの塩及び固体形態、並びにそれらを含有する組成物及び使用方法 |
Country Status (38)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8491927B2 (en) * | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
| LT3202461T (lt) | 2010-02-11 | 2019-04-25 | Celgene Corporation | Arilmetoksiizoindolino dariniai ir juos apimančios kompozicijos bei jų panaudojimo būdai |
| AU2012236655B2 (en) | 2011-03-28 | 2016-09-22 | Deuterx, Llc, | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| JP6419072B2 (ja) | 2012-08-09 | 2018-11-07 | セルジーン コーポレイション | （ｓ）−３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンの塩及び固体形態、並びにそれらを含有する組成物及び使用方法 |
| WO2014110558A1 (en) | 2013-01-14 | 2014-07-17 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| US9695145B2 (en) | 2013-01-22 | 2017-07-04 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| EP2968334A4 (en) | 2013-03-14 | 2016-08-03 | Deuterx Llc | 3- (SUBSTITIERTES-4-OXO-quinazolin-3 (4H) -yl) -3-deutero-PIPERIDINE-2,6-DIONE DERIVATIVES |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| WO2018102725A1 (en) | 2016-12-01 | 2018-06-07 | Arvinas, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
| WO2018140671A1 (en) * | 2017-01-27 | 2018-08-02 | Celgene Corporation | 3-(1-oxo-4-((4-((3-oxomorpholino) methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof |
| EA202090103A1 (ru) | 2017-06-22 | 2020-04-24 | Селджин Корпорейшн | Лечение гепатоцеллюлярной карциномы, которая характеризуется вирусной инфекцией гепатита b |
| EP3860610A4 (en) | 2018-10-01 | 2022-06-15 | Celgene Corporation | COMBINATION THERAPY FOR THE TREATMENT OF CANCER |
| EP3876958A1 (en) | 2018-11-08 | 2021-09-15 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
| AU2020336309A1 (en) | 2019-08-26 | 2022-03-17 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| IL292375A (en) * | 2019-10-21 | 2022-06-01 | Celgene Corp | Solid forms include (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)metyl)benzyl)amino)isoindoline-1 3- Discussion and salts from them, and preparations that include the same and their use |
| CN114980918A (zh) | 2019-11-07 | 2022-08-30 | 朱诺治疗学股份有限公司 | T细胞疗法与(s)-3-[4-(4-吗啉-4-基甲基-苄氧基)-1-氧代-1,3-二氢-异吲哚-2-基]-哌啶-2,6-二酮的组合 |
| TW202214236A (zh) * | 2020-09-14 | 2022-04-16 | 美商亞文納營運公司 | 用於靶向降解雌激素受體之化合物之結晶及非晶形形式 |
| US11964979B2 (en) * | 2022-06-27 | 2024-04-23 | Abion Inc. | Camsylate salts of triazolopyrazine derivatives |
| WO2024064646A1 (en) | 2022-09-20 | 2024-03-28 | Celgene Corporation | Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same |
| WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
| WO2025076472A1 (en) | 2023-10-06 | 2025-04-10 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| KR890002631B1 (ko) | 1984-10-04 | 1989-07-21 | 몬산토 캄파니 | 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물 |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| WO1995003807A1 (en) | 1993-07-27 | 1995-02-09 | The University Of Sydney | Treatment of age-related macular degeneration |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| IT1274549B (it) | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
| DE69632684T2 (de) | 1995-06-27 | 2005-06-09 | Takeda Pharmaceutical Co. Ltd. | Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| CA2624949C (en) | 1996-07-24 | 2011-02-15 | Celgene Corporation | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing tnf.alpha. levels |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| ES2221019T3 (es) | 1996-10-31 | 2004-12-16 | Takeda Chemical Industries, Ltd. | Preparacion de liberacion mantenida. |
| WO1998027980A2 (en) | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
| US6001368A (en) | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| EP1356075A4 (en) | 2000-10-16 | 2005-04-13 | Compound Therapeutics Inc | PROTEIN EQUIPMENT FOR ANTIBODY MIMETICS AND OTHER TIE PROTEINS |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| ATE472609T1 (de) | 2001-04-26 | 2010-07-15 | Amgen Mountain View Inc | Kombinatorische bibliotheken von monomerdomänen |
| US20040190609A1 (en) | 2001-11-09 | 2004-09-30 | Yasuhiko Watanabe | Moving picture coding method and apparatus |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| JP5089170B2 (ja) | 2003-12-02 | 2012-12-05 | セルジーン コーポレイション | 異常ヘモグロビン症及び貧血症の治療及び管理のための方法及び組成物 |
| US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| CA2560221C (en) | 2004-03-22 | 2010-12-07 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders |
| US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| EP1755600A2 (en) | 2004-04-23 | 2007-02-28 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension |
| WO2006053160A2 (en) | 2004-11-12 | 2006-05-18 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases |
| JP2008520207A (ja) | 2004-11-16 | 2008-06-19 | アヴィディア リサーチ インスティテュート | タンパク質骨格およびその使用 |
| WO2006058008A1 (en) | 2004-11-23 | 2006-06-01 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
| US8354417B2 (en) * | 2007-09-26 | 2013-01-15 | Celgene Corporation | Solid forms comprising 3-(2,5-dimethyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same |
| LT3202461T (lt) * | 2010-02-11 | 2019-04-25 | Celgene Corporation | Arilmetoksiizoindolino dariniai ir juos apimančios kompozicijos bei jų panaudojimo būdai |
| JP6419072B2 (ja) * | 2012-08-09 | 2018-11-07 | セルジーン コーポレイション | （ｓ）−３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンの塩及び固体形態、並びにそれらを含有する組成物及び使用方法 |
-
2013
- 2013-08-08 JP JP2015526692A patent/JP6419072B2/ja active Active
- 2013-08-08 EP EP19150922.3A patent/EP3524598B1/en active Active
- 2013-08-08 PL PL13753455T patent/PL2882737T3/pl unknown
- 2013-08-08 PE PE2015000170A patent/PE20150617A1/es not_active Application Discontinuation
- 2013-08-08 CA CA2878954A patent/CA2878954C/en active Active
- 2013-08-08 TR TR2019/04785T patent/TR201904785T4/tr unknown
- 2013-08-08 ES ES19150922T patent/ES2885769T3/es active Active
- 2013-08-08 CN CN201380052471.0A patent/CN104703978B/zh active Active
- 2013-08-08 SG SG11201500999WA patent/SG11201500999WA/en unknown
- 2013-08-08 LT LTEP13753455.8T patent/LT2882737T/lt unknown
- 2013-08-08 PT PT13753455T patent/PT2882737T/pt unknown
- 2013-08-08 TW TW102128555A patent/TW201408657A/zh unknown
- 2013-08-08 MX MX2018011777A patent/MX383025B/es unknown
- 2013-08-08 HR HRP20190398TT patent/HRP20190398T1/hr unknown
- 2013-08-08 CN CN201810299519.2A patent/CN108484571B/zh active Active
- 2013-08-08 WO PCT/US2013/054064 patent/WO2014025964A2/en not_active Ceased
- 2013-08-08 SI SI201331362T patent/SI2882737T1/sl unknown
- 2013-08-08 SM SM20190240T patent/SMT201900240T1/it unknown
- 2013-08-08 KR KR1020157006134A patent/KR20150041123A/ko not_active Withdrawn
- 2013-08-08 IN IN885DEN2015 patent/IN2015DN00885A/en unknown
- 2013-08-08 RS RS20190420A patent/RS58548B1/sr unknown
- 2013-08-08 AU AU2013299631A patent/AU2013299631B2/en active Active
- 2013-08-08 EP EP21183734.9A patent/EP3950681A3/en active Pending
- 2013-08-08 EA EA201590330A patent/EA201590330A1/ru unknown
- 2013-08-08 DK DK13753455.8T patent/DK2882737T3/da active
- 2013-08-08 EP EP13753455.8A patent/EP2882737B1/en active Active
- 2013-08-08 US US13/962,745 patent/US9221788B2/en active Active
- 2013-08-08 UA UAA201501974A patent/UA114521C2/uk unknown
- 2013-08-08 AR ARP130102836A patent/AR094997A1/es unknown
- 2013-08-08 HK HK15112291.4A patent/HK1211576A1/xx unknown
- 2013-08-08 HU HUE13753455A patent/HUE042685T2/hu unknown
- 2013-08-08 BR BR112015001874A patent/BR112015001874A2/pt not_active Application Discontinuation
- 2013-08-08 NZ NZ628030A patent/NZ628030A/en not_active IP Right Cessation
- 2013-08-08 ES ES13753455T patent/ES2723277T3/es active Active
- 2013-08-08 MX MX2015001636A patent/MX359508B/es active IP Right Grant
-
2015
- 2015-01-16 ZA ZA2015/00326A patent/ZA201500326B/en unknown
- 2015-01-25 IL IL236922A patent/IL236922A0/en unknown
- 2015-02-05 CR CR20150050A patent/CR20150050A/es unknown
- 2015-02-05 MX MX2021006091A patent/MX2021006091A/es unknown
- 2015-02-05 EC ECIEPI20154234A patent/ECSP15004234A/es unknown
- 2015-02-06 CL CL2015000291A patent/CL2015000291A1/es unknown
- 2015-02-09 SA SA515360022A patent/SA515360022B1/ar unknown
- 2015-02-09 PH PH12015500275A patent/PH12015500275A1/en unknown
- 2015-11-18 US US14/945,147 patent/US9629849B2/en active Active
-
2017
- 2017-02-28 US US15/445,070 patent/US9884062B2/en active Active
- 2017-12-28 US US15/856,845 patent/US10463672B2/en active Active
-
2018
- 2018-07-19 JP JP2018135444A patent/JP6954869B2/ja active Active
-
2019
- 2019-04-02 CY CY20191100369T patent/CY1121592T1/el unknown
- 2019-06-17 US US16/443,161 patent/US10596180B2/en active Active
-
2020
- 2020-02-25 US US16/800,979 patent/US11241439B2/en active Active
- 2020-05-01 JP JP2020081266A patent/JP7174735B2/ja active Active
-
2022
- 2022-01-06 US US17/570,299 patent/US20220125797A1/en not_active Abandoned
- 2022-08-10 JP JP2022127689A patent/JP7431900B2/ja active Active
-
2024
- 2024-07-03 US US18/763,262 patent/US12343346B2/en active Active
-
2025
- 2025-05-23 US US19/217,914 patent/US20250281501A1/en active Pending